Loxo Oncology, Inc. (LOXO) Traders Should Start Listening to Analysts

Loxo Oncology, Inc. (LOXO) shares saw a recent bid of $70.12 and 5.9M shares have exchanged hands in the recent trading session, yielding a 47.81% gain over the past week. The stock price increased 43.16% or $-21.14 versus $48.98 at the end of the prior session. This change led market cap to move at $1.76B, putting the price 37.46% below the 52-week high and 309.10% above the 52-week low. The company’s stock has a normal trading capacity of 205.26K shares while the relative volume is 28.74.

To stay one step ahead we extended our research by comparing different price targets. The stock notched a 12-month high of $51.83 while $59.00 target is by far the most aggressive out of analysts who are currently evaluating the company, $7.17 higher than the next highest 52-week price estimate. The lowest 12-month price target for the shares is $45.00, which would be decrease of about -36% of its current value. The mean target of $52.00 should be compared with the price when the stock was languishing around $17.14 a share. And it remains to be seen which target price LOXO can achieve without sacrificing much as the company is holding a 157.32% gain for the past twelve months.

By historical standards, Loxo Oncology, Inc. remains a cheap stock. For now, Loxo Oncology, Inc. is the toast of Wall Street as its ABR stands at 1.90 with 2 out of 7 analysts rating the stock a buy. Over the short term, some market observers may have noticed that Loxo Oncology, Inc. has a 17.75% short float with 15 days to cover. It becomes significant when you consider how many shares are shorted versus the average daily volume, means how many days to cover those short shares at that volume. Loxo Oncology, Inc. has far performed well this year, with the share price up 118.34% since January. Over the past 2 quarters, the stock is up 164.11%, compared with a gain of nearly 56.41% for 3 months and about 59.51% for the past 30 days.

Last time, the company failed Wall Street by reporting EPS of $-0.96, smashing the consensus of $-0.90 per share. Revenue for the quarter also killed consensus, coming in at $0M, compared to the consensus of 0M. Nonetheless, from here on out, earnings per share forecasts for the current quarter are $-0.99. The company is expected to report EPS as high as $-0.91 and as low as $-1.05 per share. Similarly, full-year EPS forecasts have ranged between $-4.51 and $-3.93. The mean EPS estimate is $-4.22. On the other side, sales forecasts for the current quarter are $0M. The stock is expected to report revenue as high as $0M and as low as $0M per share. Similarly, full-year sales forecasts have ranged between $0M and $0M. The mean revenue estimate is $0M.

Over the last 5 years, Analysts are expecting EPS growth rates to be at -63.10% this quarter and EPS estimate for next year reflect -5.20% growth rate.

Sell-side analysts also have something to say about this company. Citigroup raised its rating on Loxo Oncology, Inc. to Buy on 05/06/2017 in a reversal from its prior Neutral rating. Stifel analysts stated on 05/06/2017 that they maintained their Buy rating. Morgan Stanley analysts stated on 03/04/2017 that they launched coverage on this stock with Overweight rating. Citigroup had a markedly different take on 10/03/2017, proposing that Loxo Oncology, Inc. is now considered Neutral versus prior Buy rating.

Loxo Oncology, Inc. (LOXO) Traders Should Start Listening to Analysts was last modified: June 6th, 2017 by Caleb Gerald
Stock News Magazine
Now there is no need to go through dozens of information portals, collecting a bit of the picture of the day. All the latest news from the region, the country, the world, you can find on the newsline of our site. The loudest incidents, interesting events, current opinions, people in the spotlight and much more – we gathered for you in one place.